Sendoxan 50 mg overtrukne tabletter Danija - danų - Lægemiddelstyrelsen (Danish Medicines Agency)

sendoxan 50 mg overtrukne tabletter

baxter a/s - cyclophosphamid, vandfrit - overtrukne tabletter - 50 mg

Sendoxan 200 mg pulver til injektionsvæske, opløsning Danija - danų - Lægemiddelstyrelsen (Danish Medicines Agency)

sendoxan 200 mg pulver til injektionsvæske, opløsning

baxter a/s - cyclophosphamid, vandfrit - pulver til injektionsvæske, opløsning - 200 mg

Azacitidine Celgene Europos Sąjunga - danų - EMA (European Medicines Agency)

azacitidine celgene

celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Trecondi Europos Sąjunga - danų - EMA (European Medicines Agency)

trecondi

medac gesellschaft für klinische spezialpräparate mbh - treosulfan - hematopoietisk stamcelletransplantation - antineoplastiske midler - treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (allohsct) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.

Isomex 30 mg depottabletter Danija - danų - Lægemiddelstyrelsen (Danish Medicines Agency)

isomex 30 mg depottabletter

2care4 aps - isosorbidmononitrat, fortyndet - depottabletter - 30 mg

Phelinun Europos Sąjunga - danų - EMA (European Medicines Agency)

phelinun

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastiske midler - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.